Nail Psoriasis on Feet Treatment 2026 | DPM

Feature	Nail Psoriasis	Onychomycosis (Fungal)	Nail Trauma
Pitting	Common — pathognomonic; small uniform holes	Absent	Absent (unless nail matrix damaged)
Oil drop sign	Present — salmon/yellow translucent patch under nail	Absent	Absent
Onycholysis	Yes — from distal edge; irregular border	Yes — but usually more distal/lateral; irregular	Yes — usually from one edge; history of injury
Subungual debris	White chalky; non-crumbly compared to fungus	Yellow-brown; crumbly; foul odor possible	Usually none or blood
KOH prep / fungal culture	Negative (unless coinfection)	Positive (>50% of clinically suspected cases)	Negative
Associated skin disease	Plaque psoriasis in 80–90%; check elbows, scalp, knees	Usually none; tinea pedis may coexist	None
Finger vs toe distribution	Both hands and feet equally	Predominantly toenails (70%)	Corresponds to trauma site

Treatment	Mechanism	Best For	Evidence Level	Practical Consideration
Topical corticosteroid (clobetasol)	Reduces inflammation at nail matrix and nail bed	Mild-moderate psoriatic nail; pitting; onycholysis	Level 2	Apply under occlusion nightly; months of treatment required
Intralesional triamcinolone injection	Direct anti-inflammatory at nail matrix	Pitting; matrix-dominant disease; moderate severity	Level 2	Painful; local anesthetic required; highly effective for pitting
Calcipotriol (Dovonex)	Vitamin D analogue; normalizes keratinocyte differentiation	Subungual hyperkeratosis; mild disease	Level 2	Apply to proximal nail fold; less effective than steroids for pitting
Methotrexate	Systemic immunosuppression; anti-proliferative	Extensive nail + skin psoriasis; psoriatic arthritis	Level 2	Requires monitoring (LFTs, CBC); contraindicated in liver disease/pregnancy
Biologics (adalimumab, secukinumab, ixekizumab)	Targeted cytokine blockade (TNF-α, IL-17, IL-23)	Severe nail psoriasis + skin psoriasis; psoriatic arthritis	Level 1	Most effective; high cost; requires rheumatology/derm involvement
Nail avulsion + topical	Removes nail plate for direct matrix drug access	Severe single nail; before systemic therapy	Level 2	Chemical (urea 40%) or surgical; temporary but enables better drug penetration

What Is Nail Psoriasis

Nail psoriasis is the involvement of the nail unit — the nail matrix, nail bed, and surrounding tissues — by the same inflammatory process that drives psoriatic skin disease. The nail matrix produces the nail plate; inflammatory infiltration of the matrix disrupts normal keratinization and creates the characteristic surface abnormalities (pitting, ridging, crumbling). Inflammatory changes in the nail bed produce the oil drop sign and subungual hyperkeratosis. Any part of the nail unit can be affected, and the predominant finding reflects which anatomical compartment bears the greatest inflammation burden at any given time.

In our clinic, nail psoriasis presents in three ways: patients who know they have psoriasis and notice their toenails are changing, patients with toenail changes who have no diagnosed skin psoriasis and are surprised to learn their nails may be the first manifestation, and patients who have been treated for presumed fungal nail disease for months or years with no improvement because the actual diagnosis is psoriasis — or psoriasis with superimposed fungal infection. Getting the diagnosis right early matters because the treatment approaches are completely different, and psoriatic nail disease carries significant implications for systemic psoriatic arthritis risk.

Nail Psoriasis Signs by Nail Unit Location

Nail Matrix Involvement — Surface Plate Abnormalities

Psoriatic inflammation of the proximal nail matrix produces pitting — discrete, punctate depressions in the nail plate surface that look like ice-pick marks. Pits are the most common nail psoriasis finding and affect up to 68% of patients with nail psoriasis. They vary in size (0.5-2 mm) and depth; psoriatic pits tend to be larger and more irregular than the fine, uniform pits of alopecia areata. The mid-matrix produces leukonychia (white areas in the plate). The distal matrix produces red spots in the lunula. Severe matrix inflammation causes onychorrhexis (longitudinal ridging), Beau’s lines (transverse grooves indicating arrest of growth), and nail plate crumbling or complete nail destruction.

Nail Bed Involvement — Oil Drop Sign and Hyperkeratosis

The oil drop sign (also called the salmon patch) is pathognomonic for nail psoriasis when present — a translucent, yellow-pink to salmon-colored area visible through the nail plate, caused by focal psoriatic inflammation of the nail bed beneath an intact plate. It resembles a drop of oil viewed through the nail. Subungual hyperkeratosis — chalky, powdery buildup of scale under the distal nail plate — results from psoriatic epidermal hyperproliferation in the nail bed and hyponychium. This is often the finding that most closely mimics onychomycosis. Splinter hemorrhages (thin, dark red-brown longitudinal streaks under the nail plate) occur from nail bed vessel fragility. Onycholysis (separation of the nail plate from the bed, starting distally) is common and creates an entry point for secondary fungal or bacterial infection.

NAPSI Scoring — Measuring Disease Severity

The Nail Psoriasis Severity Index (NAPSI) provides a standardized method for grading nail psoriasis severity, which is important for treatment decisions and monitoring response to systemic therapy. Each nail is divided into four quadrants. Matrix signs (pitting, leukonychia, red spots in lunula, nail plate crumbling) are scored 0-4 based on how many quadrants are affected. Nail bed signs (oil drop sign, onycholysis, subungual hyperkeratosis, splinter hemorrhages) are similarly scored 0-4. Each nail scores 0-8; all 20 nails give a maximum NAPSI of 160. A NAPSI of 20 or higher is often used as a threshold for systemic treatment consideration. In clinical practice, NAPSI is used primarily in research and in monitoring response to biologic therapy.

Distinguishing Nail Psoriasis from Onychomycosis

This is the most clinically important differential in nail disease, and it cannot be reliably made on clinical appearance alone. Both conditions produce subungual hyperkeratosis, onycholysis, and nail plate thickening. Onychomycosis tends to start distally (distal subungual pattern), affects one or two nails asymmetrically, and produces yellow-white discoloration with nail crumbling. Nail psoriasis more commonly affects multiple nails simultaneously and symmetrically, is associated with skin psoriasis elsewhere, and produces the pathognomonic oil drop sign and pitting — findings not seen in onychomycosis. However, coexistence is common: psoriatic onycholysis creates the warm, moist subungual space that predisposes to fungal colonization, and 30% of patients with nail psoriasis have concurrent fungal nail disease.

The definitive distinguishing test is nail clipping sent for KOH examination and fungal culture. A positive culture confirms fungal infection requiring antifungal treatment — but does not exclude coexisting psoriasis. A negative culture in a patient with nail changes and personal or family history of psoriasis, psoriatic arthritis, or skin psoriasis points strongly toward psoriatic nail disease. Dermoscopy is increasingly used to distinguish the two: the oil drop sign and dilated capillary loops in the distal nail fold are psoriasis-specific; the “aurora borealis” pattern (white-yellow discoloration) favors onychomycosis.

Nail Psoriasis and Psoriatic Arthritis

Nail psoriasis is the strongest clinical predictor of psoriatic arthritis development in patients with skin psoriasis. Patients with nail involvement have a 3-fold higher risk of developing psoriatic arthritis compared to psoriasis patients without nail disease. In some patients, nail psoriasis precedes any skin involvement by years — making it a potential early marker of systemic psoriatic disease before other manifestations emerge. The entheseal theory explains this connection: the nail unit is mechanically connected to the distal interphalangeal joint through shared entheseal tissue, and the inflammatory process that causes nail psoriasis extends to the DIP joint, driving psoriatic arthritis. Any patient presenting with isolated nail psoriasis should be evaluated for joint symptoms and referred to rheumatology if DIP swelling, morning stiffness, or dactylitis (sausage digit) are present.

Treatment Options

Topical Treatments — First Line for Mild Disease

Topical corticosteroids (class I-II, such as clobetasol propionate 0.05%) applied under occlusion to the nail fold and hyponychium are first-line for mild nail psoriasis. Penetration through the nail plate is limited; the periungual application method — applying the steroid to the proximal nail fold and lateral nail folds rather than the plate surface — improves delivery to the underlying matrix. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are alternatives when steroid side effects (skin atrophy around the nail) are a concern. Topical vitamin D analogues (calcipotriol) and tazarotene (retinoid) reduce nail bed hyperkeratosis and have modest evidence for nail matrix disease. Topical treatments require 3-6 months of consistent application before meaningful response can be assessed — the entire nail must grow out under the treatment effect.

Intralesional Corticosteroid Injections

Intralesional triamcinolone acetonide injected into the proximal nail fold is significantly more effective than topical therapy for nail matrix involvement (pitting, ridging, leukonychia). The injection delivers corticosteroid directly to the inflamed matrix, bypassing the barrier of the nail plate. The procedure is performed under digital block anesthesia; without adequate anesthesia it is quite painful due to the pressure in the confined nail fold space. Injections are typically repeated every 4-8 weeks for 3-6 months. Complications include nail plate thinning, subungual hematoma, and injection site atrophy — all generally temporary. In our clinic, intralesional injection is our preferred intervention for patients with moderate nail matrix disease and significant cosmetic or functional impact who do not yet meet criteria for systemic therapy.

Systemic and Biologic Therapy

Moderate-to-severe nail psoriasis (NAPSI 20 or higher, or any nail disease accompanied by active psoriatic arthritis) warrants systemic treatment. Traditional systemic agents — methotrexate, cyclosporine, acitretin — produce modest nail improvement. Biologic agents targeting TNF-alpha (adalimumab, etanercept), IL-17A (secukinumab, ixekizumab), and IL-23 (guselkumab, risankizumab) produce substantially greater nail clearing rates, with IL-17 inhibitors showing the highest efficacy for nail psoriasis specifically (NAPSI 70-90% reduction in trials). The JAK inhibitor tofacitinib has also demonstrated nail benefit. Biologic therapy decisions are made in coordination with dermatology or rheumatology; the podiatric role is to identify nail psoriasis accurately, initiate the treatment ladder, and manage the mechanical consequences of nail destruction.

Podiatric Mechanical Management

Beyond pharmacologic treatment, the podiatric role in nail psoriasis management includes: regular professional nail debridement to reduce subungual hyperkeratosis burden (which reduces nail plate pressure and pain), treating concurrent onychomycosis when culture-confirmed (topical efinaconazole or oral terbinafine depending on severity — oral antifungals are appropriate only when fungal coinfection is confirmed, not empirically), fitting guidance for footwear that minimizes pressure on dystrophic nails, and managing the mechanical complications of chronic onycholysis including ingrown nail tendencies and secondary bacterial paronychia. Custom orthotics that redistribute pressure off psoriatic toenails can significantly reduce pain during flares.

Not ideal for: Active nail disease with open subungual areas. PowerStep Pinnacle insoles reduce pressure on the forefoot and toes, providing meaningful pain relief for patients with psoriatic nail thickening and subungual hyperkeratosis that makes shoe wear uncomfortable.

Not ideal for: Broken periungual skin or open psoriatic plaques. Doctor Hoy’s natural arnica gel provides topical relief for the periungual tenderness and mild soft tissue inflammation around psoriatic toenails with intact skin.

Frequently Asked Questions

How do you tell nail psoriasis from a fungal nail

Clinically, the oil drop sign (salmon-colored spot under the nail plate) and pitting (ice-pick depressions on the nail surface) are specific to nail psoriasis and are not produced by fungal infection. Nail psoriasis also tends to affect multiple nails symmetrically and is associated with psoriatic plaques elsewhere on the skin or joints. The definitive distinction requires a nail clipping sent for KOH examination and fungal culture — psoriatic nails culture negative, fungal nails culture positive. Keep in mind that both can coexist: 30% of psoriatic nails also have concurrent fungal infection.

Can nail psoriasis be cured

Nail psoriasis cannot be permanently cured because it is driven by the same immune dysregulation that causes skin and joint psoriasis — a systemic condition that persists lifelong. However, it can be effectively controlled. Mild disease often responds well to topical corticosteroids and intralesional injections. Moderate-to-severe disease and disease associated with psoriatic arthritis responds dramatically to biologic agents, with IL-17 inhibitors achieving 70-90% nail clearing in clinical trials. Many patients achieve complete nail clearing on appropriate systemic therapy, with relapse occurring if treatment is stopped.

Does nail psoriasis mean I will get psoriatic arthritis

Nail psoriasis significantly increases psoriatic arthritis risk — patients with nail involvement are approximately 3 times more likely to develop psoriatic arthritis than those with skin psoriasis alone. However, nail psoriasis does not guarantee arthritis development; many patients have nail disease for years or decades without developing joint involvement. The warning signs that suggest early psoriatic arthritis are emerging include DIP joint swelling or tenderness, morning stiffness lasting more than 30 minutes, dactylitis (a whole digit swells uniformly — “sausage toe”), and new onset tendon or ligament insertion pain (enthesitis). If any of these develop, prompt rheumatology evaluation can catch psoriatic arthritis early, when treatment is most effective at preventing joint damage.

The Bottom Line

Nail psoriasis is underdiagnosed, frequently misidentified as onychomycosis, and undertreated — partly because its connection to systemic psoriatic disease is underappreciated, and partly because the nails are an afterthought in dermatology evaluations focused on skin plaques. The clinical stakes of getting it right are significant: nail psoriasis predicts psoriatic arthritis, biologics have transformed the treatment landscape for both, and years of failed antifungal treatment represent both cost and missed opportunity. If your toenails have pitting, oil drop spots, or subungual hyperkeratosis that has not responded to antifungal treatment, nail psoriasis needs to be on the diagnostic table — regardless of whether you have a psoriasis diagnosis or not.

Sources

1. Langenbruch A, et al. “Nail involvement as a predictor of psoriatic arthritis in patients with psoriasis.” Br J Dermatol. 2014.
2. Tan ES, et al. “Comparative efficacy of biologic therapies for the treatment of nail psoriasis: a network meta-analysis.” J Am Acad Dermatol. 2021.
3. Piraccini BM, Tosti A. “White superficial onychomycosis: epidemiological, clinical, and pathological study of 79 patients.” Arch Dermatol. 2004.
4. Schons KR, et al. “Nail psoriasis: a review of the literature.” An Bras Dermatol. 2014.
5. McGonagle D, et al. “The nail as a musculoskeletal appendage — implications for an improved understanding of the link between psoriasis and arthritis.” Dermatology. 2009.

In-Office Treatment at Balance Foot & Ankle

If home treatment isn’t providing relief for your nail psoriasis foot, our podiatry team at Balance Foot & Ankle can help with same-day evaluations and advanced in-office care.

American Academy of Dermatology: Nail Psoriasis